Dacogen

Anemia, Anemia, Refractory, Anemia + 6 more
Treatment
20 Active Studies for Dacogen

What is Dacogen

DecitabineThe Generic name of this drug
Treatment SummaryMyelodysplastic syndromes (MDS) are a group of blood disorders caused by abnormal cells in the bone marrow. MDS can lead to a decrease in white and red blood cells, as well as platelets. In some cases, MDS can develop into acute myeloid leukemia, which is very serious. Decitabine is a medication approved by the FDA in 2006 to treat MDS. It works by preventing DNA methyltransferase from working, leading to a decrease in the number of abnormal cells. Decitabine is usually given intravenously, but it can also be taken orally in combination with
Dacogenis the brand name
Dacogen Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dacogen
Decitabine
1996
36

Effectiveness

How Dacogen Affects PatientsDecitabine is a drug that changes how certain genes work in the body. Taking decitabine can result in a decrease in white blood cells and platelets, and can be harmful to a fetus if taken by a pregnant woman. It is important for those taking decitabine to practice effective contraception and avoid pregnancy.
How Dacogen works in the bodyDecitabine is used to treat myelodysplastic syndromes, a type of cancer that affects the white blood cells. Decitabine works by stopping the action of enzymes that add a chemical tag to certain genes, called DNA methylation. This causes the cancer cells to stop growing and die. It also causes genes that suppress tumors to become active, working to stop the cancer from spreading. Decitabine may also change how genes are expressed, alter histone modifications, and activate pathways involved in DNA damage response. The overall effect is to slow or stop cancer cell growth.

When to interrupt dosage

The measure of Dacogen depends upon the diagnosed state, such as Chronic Myelomonocytic Leukemia, Anemia and Refractory anemias. The amount likewise fluctuates, in line with the delivery mode (e.g. Intravenous or Injection, powder, for solution) delineated in the table beneath.
Condition
Dosage
Administration
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Anemia, Refractory
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Chronic Myelomonocytic Leukemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Myelodysplastic Syndrome
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
IPSS High Risk
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Myelodysplastic Syndromes
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Myelodysplastic Syndromes
, 5.0 mg/mL, 50.0 mg, 35.0 mg
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Dacogen.
Common Dacogen Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Acteoside.
Dacogen Toxicity & Overdose RiskDecitabine has been found to have mutagenic and damaging effects in certain tests on animals, including decreased weight and fertility in mice exposed to it in utero, and decreased sperm count and fertility in adult male mice treated with a high dose. An overdose of decitabine can cause decreased production of white and red blood cells and platelets, as well as other severe side effects. There is no antidote for decitabine overdose, so patients should be provided with supportive care.

Dacogen Novel Uses: Which Conditions Have a Clinical Trial Featuring Dacogen?

183 active research projects are currently underway to assess the potential of Dacogen to mitigate Anemia, Refractory Anemia and Myelodysplastic Syndrome.
Condition
Clinical Trials
Trial Phases
Myelodysplastic Syndrome
126 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Phase 4
Chronic Myelomonocytic Leukemia
54 Actively Recruiting
Phase 1, Phase 2, Phase 3, Early Phase 1
Anemia
0 Actively Recruiting
Anemia
0 Actively Recruiting
Anemia
0 Actively Recruiting
Anemia, Refractory
0 Actively Recruiting
IPSS High Risk
0 Actively Recruiting
Myelodysplastic Syndromes
0 Actively Recruiting
Myelodysplastic Syndromes
0 Actively Recruiting

Dacogen Reviews: What are patients saying about Dacogen?

5Patient Review
12/15/2011
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
I've been on Dacogen for three months now, and it's going well. I have to get IV treatments every five days, followed by three weeks off. It's lowered my white blood cell count, so I've needed a few transfusions of red blood cells. But things are looking up – my hemoglobin is rising without any assistance, and I'm feeling stronger every day.
5Patient Review
4/25/2009
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
4.7Patient Review
7/24/2011
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
Dacogen has been working well for me over the past year and a half. My blood counts are finally in the safer range, but I have developed slightly increased levels of sugar in my blood, so I may need to start medication for diabetes.
3.7Patient Review
10/1/2011
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
I've been on this medication since my diagnosis of myleodysplasia 23 months ago. My blood counts are now completely normal, but my white blood cells fluctuate a bit below normal.
3.3Patient Review
10/10/2009
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
I've been on this treatment for a year now, and it seems to be working. I haven't needed blood transfusions, so that's good. Thank you, Jesus.
2Patient Review
7/7/2014
Dacogen for Bone Marrow Disorders Occurring Before Leukemia
My mother has leukemia and is currently taking Dacogne.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dacogen

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Dacogen chemo?

"Dacogen, in the form of decitabine, is an antineoplastic medication used to treat myelodysplastic syndromes, which are certain types of blood or bone marrow cancer. Generic forms of Dacogen are available."

Answered by AI

How is Dacogen administered?

"DACOGEN should be given at a dose of 15 mg/m2 over the course of 3 hours by continuous intravenous infusion. This should be repeated every 8 hours for 3 days. After this, cycles should be repeated every 6 weeks, but only if the patient has regained enough blood cells and platelets (ANC at least 1,000/µL and platelets at least 50,000/µL). A minimum of 4 cycles is recommended."

Answered by AI

What type of drug is Dacogen?

"The medicine Dacogen is used to treat symptoms of blood or bone marrow cancer, specifically myelodysplastic syndromes. It can be used on its own or with other medications, and belongs to a class of drugs known as antineoplastics and DNA methylation inhibitors."

Answered by AI

What is Dacogen drug used for?

"This medication is used to treat myelodysplastic syndromes (MDS), a group of disorders in which the bone marrow does not produce enough healthy blood cells. People with MDS may have problems such as infections, anemia, and easy bleeding/bruising."

Answered by AI

Clinical Trials for Dacogen

Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.
Phase 2
Waitlist Available
OHSU Knight Cancer InstituteCurtis A Lachowiez
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Combination Therapy for Acute Myeloid Leukemia

18+
All Sexes
Seattle, WA
This phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, called total body irradiation (TBI), and donor hematopoietic cell transplant (HCT) works in treating adults age 60 and older with newly diagnosed adverse-risk acute myeloid leukemia (AML) or other high-grade myeloid cancer. Despite advances in supportive care and the approval of more than 10 new drugs since 2017, the outcomes of older adults with adverse-risk acute myeloid leukemia and other high-grade myeloid cancers remains poor. Most patients are expected to die from their cancer or the consequences of treatment-related side effects. Donor HCT is a very important part of any curative-cancer treatment for these patients. However, while accepted as standard care for decades, this treatment exposes patients to long periods of drug-induced low blood cell counts and the problems associated with low blood counts, like infections and bleeding, which are associated with significant risk of chronic side effects and death. This study will use a different approach to the upfront curative-cancer treatment of older adults with an adverse-risk AML or other high-grade myeloid cancer. This study will use intense chemotherapy followed a few days later by lower-dose TBI and donor HCT. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. This approach allows effective treatment of cancer cells and overall reduction of the period of low blood cells counts. This decreases the risk for problems associated with low blood counts, such as infection and chronic side effects. Decreasing these are important for older adults who undergo HCT. This treatment strategy may improve treatment outcomes by allowing more patients to successfully undergo donor HCT and reduce the risk of low blood cell counts and the problems associated with low blood counts. Giving chemotherapy followed immediately by reduced-intensity TBI and donor HCT may be safe, tolerable and/or effective in treating adults age 60 and older with newly diagnosed adverse-risk AML or other high-grade myeloid cancer.
Phase 2
Recruiting
Fred Hutch/University of Washington Cancer ConsortiumFilippo Milano, MD, PhD
Have you considered Dacogen clinical trials? We made a collection of clinical trials featuring Dacogen, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Emapalumab for Graft-versus-Host Disease

18 - 75
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.
Phase 1
Waitlist Available
City of Hope Medical CenterAmandeep Salhotra
Image of Rare Disease Research in Atlanta, United States.

EPI-321 for Muscular Dystrophy

18 - 75
All Sexes
Atlanta, GA
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.
Phase 1 & 2
Recruiting
Rare Disease Research (+3 Sites)Epicrispr Biotechnologies, Inc.
Have you considered Dacogen clinical trials? We made a collection of clinical trials featuring Dacogen, we think they might fit your search criteria.Go to Trials
Image of Children's Hospital of Philadelphia in Philadelphia, United States.

CD45RA Depleted Stem Cell Addback for Leukemia

1 - 25
All Sexes
Philadelphia, PA
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.
Phase 1 & 2
Recruiting
Children's Hospital of PhiladelphiaTimothy Olson, MD, PhD
Image of City of Hope Medical Center in Duarte, United States.

Vedolizumab + Cyclophosphamide + Tacrolimus for Graft-versus-Host Disease

18 - 80
All Sexes
Duarte, CA
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.
Phase 2
Recruiting
City of Hope Medical CenterMonzr M. Al Malki
Image of University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center in Cleveland, United States.

Abatacept for Leukemia

18 - 65
All Sexes
Cleveland, OH
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.
Phase 2
Recruiting
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterLeland Metheny, MD
Have you considered Dacogen clinical trials? We made a collection of clinical trials featuring Dacogen, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security